Company: Ception Therapeutics [1]
Based: Malvern, PA
Amount: $77.7M
Round: Third
Investors: Aperture Venture Partners, Essex Woodlands Health Ventures, Greenlight Capital, Individuals, Investor Growth Capital, Lumira Capital Corporation, New Science Ventures, Undisclosed Investor
Scoop: Ception's pipeline includes a late-stage biologic agent (Anti-IL5 MAb) in clinical development for eosinophilic esophagitis and other inflammatory conditions. The company is also working on an oral Anti-TNF drug, an anti-infective program and a novel anti-thrombotic program.
More News:
Ception adds $14.7M to big third round. Report [2]
Ception Therapeutics pockets $63M in third round. Report [3]
Links:
[1] http://www.ceptiontx.com/
[2] http://www.fiercebiotech.com/story/ception-adds-14.7m-to-big-third-round/2007-05-31
[3] http://www.fiercebiotech.com/story/ception-therapeutics-pockets-63m-in-third-round/2007-01-30
[4] http://www.fiercebiotech.com/special-reports/zogenix-top-20-vc-deals-2007
[5] http://www.fiercebiotech.com/special-reports/top-20-venture-capital-deals-2007
[6] http://www.fiercebiotech.com/special-reports/targanta-therapeutics-top-20-vc-deals-2007